Kai Schulze
Department of Vaccinology and Applied Microbiology
Helmholtz Centre for Infection Research
Kai Schulze has not added Biography.
If you are Kai Schulze and would like to personalize this page please email our Author Liaison for assistance.
The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties.
Vaccine Feb, 2007 | Pubmed ID: 17187906
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
Clinical and vaccine immunology : CVI Aug, 2007 | Pubmed ID: 17567766
A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties.
Journal of immunology (Baltimore, Md. : 1950) Aug, 2007 | Pubmed ID: 17675464
The FAI protein of group C streptococci acts as a mucosal adjuvant by the specific targeting and activation of B cells.
International journal of medical microbiology : IJMM Jan, 2008 | Pubmed ID: 17884726
Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.
Vaccine Jul, 2011 | Pubmed ID: 21619907
Development and characterization of attenuated metabolic mutants of Bordetella bronchiseptica for applications in vaccinology.
Environmental microbiology Jan, 2013 | Pubmed ID: 22676396
Vaccine adjuvants: key tools for innovative vaccine design.
Current topics in medicinal chemistry , 2013 | Pubmed ID: 24066891
Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.
PloS one , 2014 | Pubmed ID: 25140692
Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation.
Nanomedicine : nanotechnology, biology, and medicine Jan, 2015 | Pubmed ID: 25200611
Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination.
Journal of controlled release : official journal of the Controlled Release Society May, 2015 | Pubmed ID: 25795506
Rodents as pre-clinical models for predicting vaccine performance in humans.
Expert review of vaccines , 2015 | Pubmed ID: 26268433
Modeling Influenza Virus Infection: A Roadmap for Influenza Research.
Viruses Oct, 2015 | Pubmed ID: 26473911
Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions.
Molecular medicine (Cambridge, Mass.) May, 2016 | Pubmed ID: 27262025
New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.
Current topics in microbiology and immunology , 2016 | Pubmed ID: 27370343
Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi.
PLoS neglected tropical diseases Feb, 2017 | Pubmed ID: 28234897
Role of Autophagy in HIV-1 Matrix Protein p17-Driven Lymphangiogenesis.
Journal of virology 08, 2017 | Pubmed ID: 28592537
Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation Pathway.
EBioMedicine Aug, 2017 | Pubmed ID: 28754303
Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
Nanomedicine : nanotechnology, biology, and medicine Nov, 2017 | Pubmed ID: 28887213
Self-replicating RNA vaccine functionality modulated by fine-tuning of polyplex delivery vehicle structure.
Journal of controlled release : official journal of the Controlled Release Society Nov, 2017 | Pubmed ID: 28935594
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice.
Frontiers in immunology , 2017 | Pubmed ID: 29033942
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved